首页> 外文期刊>感染症学雑誌 >Anti-rabies antibody titers among subjects who received rabies post-exposure prophylaxis with foreign-made rabies vaccines at the beginning and followed with Japanese rabies vaccine
【24h】

Anti-rabies antibody titers among subjects who received rabies post-exposure prophylaxis with foreign-made rabies vaccines at the beginning and followed with Japanese rabies vaccine

机译:刚开始接受国外生产的狂犬病疫苗预防狂犬病暴露的狂犬病患者的抗狂犬病抗体滴度,其次是日本狂犬病疫苗

获取原文
获取原文并翻译 | 示例
       

摘要

Recently travelers who were bitten by possibly rabid animals in rabies endemic regions and returned to Japan have increased in number. About half of them received rabies post-exposure prophylaxis (RPEP) with one or more doses of foreign-made rabies vaccines (FRV) in the local medical institutions. FRV, however, are not available in Japan so we have to continue the RPEP with Japanese rabies vaccine (JRV). It has not been demonstrated that an anti-rabies antibody induced with JRV following Vero cell rabies vaccine (PVRV) or chick embryo cell rabies vaccine (PCEC) could be high enough to prevent clinical rabies. We examined anti-rabies antibody (ARA) titers among the subjects visited our vaccine clinic to receive RPEP and obtained results as follows: the ARA titers after a total of 5 doses of PCEC or PVRV and JRV were high enough to prevent clinical rabies as after 5 doses of JRV. However, ARA titers obtained after receiving one dose of PVRV and 2 doses of JRV seemed lower than those produced after one dose of PCEC and 2 doses of JRV or 3 doses of JRV. To accelerate antibody production, consequently, the simultaneous intradermal and subcutaneous injection method of rabies vaccine may be applied to those who were bitten in their hands or head by possibly rabid animals and received only one dose of PVRV in rabies endemic regions.
机译:最近,在狂犬病流行地区被可能被狂犬病动物咬伤并返回日本的旅行者数量有所增加。大约一半的人在当地医疗机构中接受了一剂或多剂国外生产的狂犬病疫苗(FRV)的狂犬病暴露后预防(RPEP)。但是,FRV在日本尚不可用,因此我们必须继续使用日本狂犬病疫苗(JRV)进行RPEP。尚未证明在Vero细胞狂犬病疫苗(PVRV)或鸡胚细胞狂犬病疫苗(PCEC)之后用JRV诱导的抗狂犬病抗体可能足够高,可以预防临床狂犬病。我们在访问疫苗诊所接受RPEP的受试者中检查了抗狂犬病抗体(ARA)滴度,并获得了以下结果:总共5剂PCEC或PVRV和JRV服用后的ARA滴度足够高,可以预防以下的临床狂犬病5剂JRV。但是,接受一剂PVRV和2剂JRV后获得的ARA滴度似乎低于一剂PCEC和2剂JRV或3剂JRV产生的ARA效价。因此,为了加速抗体的产生,狂犬病疫苗的皮内和皮下同时注射方法可用于那些可能被狂犬病动物咬伤手或头部并且在狂犬病流行地区仅接受一剂PVRV的人群。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号